Inactive Instrument

Alexion Pharmaceuticals, Inc.

ALXN

US0153511094

Alexion Pharmaceuticals, Inc.(NasdaqGS:ALXN) dropped from S&P Biotechnology Select Industry Index

July 21, 2021 at 12:00 am EDT

Latest news about Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc.'s VOYDEYA Receives Approval in US Add-On Therapy to Ravulizumab or Eculizumab for Treatment of Extravascular Hemolysis in Adults with the Rare Disease PNH	Apr. 01	CI
Alexion Announces Long-Term Alpha Phase III Trial Data Shows Danicopan as Add-On to Standard of Care C5 Inhibitor Therapy ULTOMIRIS	Dec. 10	CI
Alexion Pharmaceuticals, Inc. completed the acquisition of Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc..	23-09-18	CI
Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases	23-09-08	CI
Alexion Pharmaceuticals, Inc. entered a definitive purchase agreement to acquire Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc. for $1 billion.	23-07-27	CI
JCR Pharmaceuticals Co., Ltd. Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoR for Neurodegenerative Disease	23-03-30	CI
Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. from a group of shareholders.	22-11-14	CI
Alexion Pharmaceuticals, Inc. Aims to Advance Nmosd Treatment Landscape with Exceptional Ultomiris® (Ravulizumab-Cwvz) Efficacy Data At Ectrims 2022	22-10-12	CI
Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. from a group of shareholders for $68.2 million.	22-10-02	CI
Alexion Pharmaceuticals, Inc Announces Danicopan Add-On to Ultomiris (Ravulizumab-Cwvz) or Soliris Met Primary Endpoint in Alpha Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis	22-09-16	CI
Alexion, Astrazeneca's Rare Disease Group and Neurimmune Closes Deal for Commercializing Ni006	22-03-01	CI
Alexion Enters into an Exclusive Global Collaboration and Licence Agreement with Neurimmune AG	22-01-07	CI
Alexion Pharmaceuticals, Inc. completed the acquisition of remaining majority stake in Caelum Biosciences, Inc. from Fortress Biotech, Inc. and others.	21-10-04	CI
AstraZeneca's Alexion to Advance and Accelerate Ongoing Phase III Clinical Development of Cael-CAEL, a Potential Medicine for AL Amyloidosis	21-09-29	CI
Alexion Pharmaceuticals, Inc. agreed to acquire remaining majority stake in Caelum Biosciences, Inc. from Fortress Biotech, Inc. and others for $500 million.	21-09-28	CI
AstraZeneca : to Mandate COVID-19 Shots for US Staff	21-08-30	MT
AstraZeneca : Rare Disease Drug Improves Copper Mobilization in Late-Stage Study	21-08-26	MT
FTSE : Consumer staples, financials lift FTSE 100 after worst week since February	21-08-20	RE
AstraZeneca : Unit Alexion Discontinues Late-Stage Trial of ALS Drug Candidate Due to Lack of Efficacy	21-08-20	MT
FTSE 100 Falls as Growth Fears Persist; More Volatility Possible	21-08-20	DJ
AstraZeneca : antibody therapy prevents COVID-19, study shows	21-08-20	RE
Alexion Discontinues CHAMPION-ALS	21-08-20	CI
AstraZeneca : Alexion to Discontinue Ultomiris Phase 3 ALS Trial	21-08-20	DJ
AstraZeneca : Exclusive - AstraZeneca exploring options for COVID-19 vaccine business - executive	21-07-29	RE
London Indexes Boosted by Positive Welcome to Most Earnings	21-07-29	DJ

Chart Alexion Pharmaceuticals, Inc.

Duration

Period

More charts

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on discovering, development and commercialization of medicines. The Company's marketed products include ULTOMIRIS, SOLIRIS (eculizumab), STRENSIQ (asfotase alfa), KANUMA (sebelipase alfa) and ANDEXXA (coagulation Factor Xa - [recombinant] inactivated-zhzo). Its ULTOMIRIS product is a long-acting C5 inhibitor, that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS product is a humanized monoclonal antibody that blocks terminal activity at the doses prescribed. Its Strensiq product is a targeted enzyme replacement therapy for patients with Hypophosphatasia (HPP). Its Kanuma product is a recombinant form of the human lysosomal acid lipase (LAL) enzyme. Its ANDEXXA product is a reversal agent for patients treated with rivaroxaban or apixaban.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+25.87%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ASTRAZENECA PLC	+7.09%	219B
ROCHE HOLDING AG	-9.12%	196B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals